Analyst upgrades: PFE, DELL DGX and SCGLY
.gif){kind=logo}
MOST NOTEWORTHY: Pfizer, Dell, Quest Diagnostics, and Societe Generale were today’s noteworthy upgrades:
- Lehman upgraded Pfizer (NYSE: PFE) to Equal Weight from Underweight on valuation.
- Friedman Billings raised Dell (NASDAQ: DELL) to Outperform from Market Perform, citing expectations for improved margins next quarter, and valuation.
- Quest Diagnostics (NYSE: DGX) was upgraded to Outperform from Neutral by Credit Suisse, which cited valuation.
- Lehman upgraded shares of Societe Generale (OTC: SCGLY) to Overweight from Underweight to reflect a potential takeoverby BNP Paribas and limited downside.
OTHER UPGRADES:
- Bayer (OTC: BAYRY) was raised to Overweight from Equal Weight by Lehman.
- Deutsche Telekom (NYSE: DT) was upgraded to Hold from Sell by Citigroup.
- Public Storage (NYSE: PSA) was raised to Buy from Hold by Deutsche Bank.
- UBS raised Entergy (NYSE: ETR) to Buy from Neutral.
Original post by Eric Buscemi
Related Articles
Analyst upgrades: NOC, GDNNY and MELI Top 10 Pre-Market Analyst Upgrades & Downgrades (MO, STZ, LVS, LYV, RF, AXP, CMS, DELL, SOLR, TIBX) Dell gets nod from analyst due to new retail partnerships Dell (DELL) Q2 earnings preview Option update: Dell-DELL volatility Up as DELL nears a six-year low
No comments yet. Be the first.
Leave a reply
